Eyegate Pharmaceuticals Inc (EYEG) 5.0000 $EYEG EyeGate

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Eyegate Pharmaceuticals Inc (EYEG) 5.0000 $EYEG

EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis
GlobeNewswire - Mon May 04, 8:03AM CDT
Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced receipt of comments from the U.S. Food & Drug Administration ("FDA" in response to questions submitted by the Company ahead of a Type B meeting scheduled for May 5, 2015. The FDA provided guidance that if the planned Phase 3 trial of EGP-437 in anterior uveitis meets non-inferiority criteria, data from this trial along with data from a previously completed Phase 3 trial in anterior uveitis will be sufficient to support a New Drug Application ("NDA" filing. The FDA also communicated that the design of the planned Phase 3 is acceptable and that the nonclinical work completed to date is sufficient to support a NDA filing. Based on this positive feedback, the Company has elected to cancel the face-to-face portion of the meeting.

EyeGate Pharmaceuticals Reports Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 31, 4:40PM CDT
Eyegate Pharmaceuticals, Inc. (OTCBB:EYEG) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced its financial results for the year ended December 31, 2014.

Eyegate Pharmaceuticals Names Michael B. Raizman, MD, Consulting Chief Medical Officer
GlobeNewswire - Mon Mar 02, 7:35AM CST
Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate" , a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the appointment of Michael B. Raizman, MD as the Consulting Chief Medical Officer. Dr. Raizman began working with the Company as a consultant in the fourth quarter of 2014.

InsiderInsights.com Daily Round Up 2/23/15: MDLZ, GPRO, MDGN, CRR
InsiderInsights - at Seeking Alpha - Tue Feb 24, 6:07AM CST

GPRO: 50.09 (-0.53), LDRH: 39.27 (+0.48), MDLZ: 40.45 (+0.40), HCOM: 25.39 (-0.11), CRR: 43.75 (-0.23), MDGN: 7.38 (-0.27), DEI: 29.50 (+0.27), WETF: 18.51 (-0.45), BBY: 34.59 (-0.23), AON: 99.55 (-0.43), GOOG: 533.85 (-4.55), LEA: 114.47 (+0.05), AJX: 13.18 (+0.10), PLAY: 33.04 (-0.03), CTSH: 63.57 (-0.25), BLPH: 8.66 (+0.14), OMI: 33.68 (+0.03)

Eyegate Pharma closes IPO
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 11:42AM CST


Eyegate Pharma prices IPO
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 6:13AM CST


IPO Market Set For Another Surge In The Healthcare Sector
Renaissance Capital IPO Research - at Seeking Alpha - Mon Feb 02, 6:15PM CST
Ten IPOs are on the IPO calendar to raise $1.4 billion, led by an $800 million offering of natural gas pipelines. The MLP is joined by a government-focused REIT as the two dividend-producing IPOs seek to price late in the week. The remaining eight...
AVGR: 11.31 (+0.07), IDGX: (), SLWD: (), ITEK: 5.80 (-0.06), REDX: (), INOV: 25.70 (+1.75), PUMP: (), CBYL: 7.70 (+0.46), NVET: 7.32 (-0.32), AAAP: ()

EyeGate Pharma back resets for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:29PM CST


Week Ahead: IPO Market Gains Momentum With 12 Deals Including Shake Shack And Health Care
Renaissance Capital IPO Research - Seeking Alpha - Tue Jan 27, 7:03AM CST
Twelve IPOs are set to raise $1 billion in the upcoming week, which would make it the busiest five-day stretch for IPOs since the week of July 28. Shake Shack's IPO offers investors a chance to own a fast-growing fast casual concept based in New...
AVGR: 11.31 (+0.07), SHAK: 69.39 (+3.89), ASND: 17.28 (-0.10), HIFR: 30.56 (+0.02), REDX: (), ONCE: 56.86 (+0.06), ENTL: 24.82 (+0.03), ZSAN: 10.41 (+0.63), FLKS: 17.17 (+0.19), LENS: 8.79 (-0.21), TCON: 12.27 (+1.41)

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mp6p4/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alcon Nordic - Allergan - AlphaMab - Amakem - BIOCAD - Boehringer Ingelheim - Charlesson - Circadian Technologies - EyeCyte - EyeGate Pharmaceuticals - F. Hoffmann-La Roche - Genzyme - Icon Bioscience - Iconic Therapeutics - Intas Pharmaceuticals - Kala Pharmaceuticals - Lpath - Mesoblast - Neurotech Pharmaceuticals - Novartis - Ohr Pharmaceutical - Omeros Corporation - Ophthotech - Oxford BioMedica - PanOptica - Pfenex - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Santen Pharmaceutical - Sanwa Kagaku Kenkyusho - Senju Pharmaceutical - TRACON Pharmaceuticals - Tacere Therapeutics - ThromboGenics - iCo Therapeutics - pSivida For more information visit http://www.researchandmarkets.com/research/9m...eovascular
AGN: 240.22 (+2.88), OHRP: 2.73 (-0.02), REGN: 489.01 (-2.42), OMER: 20.88 (-0.01), NVS: 103.75 (-0.15)

Cataract Therapeutic Pipeline Market Review by Companies and Drugs H2 2014 Report at RnRMarketResearch.com
PRWeb - Fri Nov 21, 7:31AM CST
The report "Cataract - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/cataract-pip...eport.html .

Solar Power, Biotechs Among 11 IPOs Planned This Week
at Investor's Business Daily - Mon Sep 29, 6:24PM CDT
The IPO market is maintaining a brisk pace with 11 scheduled this week, including a solar power company, three tech firms and three biotech companies. Vivint Solar (VSLR), a competitor to the Elon Musk-backed SolarCity (SCTY), plans to raise $350...
ATTO: 13.07 (-0.08), VWR: 27.40 (+0.08), JMEI: 25.35 (-1.33), ZEN: 22.29 (-0.30), VSLR: 13.92 (-0.23), JPEP: 13.34 (-0.01), W: 29.05 (+0.54), FMSA: 8.83 (+0.05), SCTY: 62.51 (-0.21), DERM: 14.97 (-0.07), AAC: 37.01 (+0.63), CALA: 11.87 (-0.27), AAVL: 35.10 (-0.85), YDLE: 14.38 (-0.25), JD: 33.40 (+0.02), BABA: 88.46 (+0.06)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 332

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 199

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 509

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 47

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 19

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 287

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 78

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 241

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading

Top 5 Most Recently Viewed Articles

John T Kim Expands Holdings with $9.65M in Amkor Tech Stock

Updated Category News Views 197

John T Kim Makes Significant Investment in Amkor Tech In a recent SEC filing, substantial insider trading activity was reported, showing that John T Kim, who holds a 10% stake in Amkor Technology Inc. (NASDAQ: AMKR), has acquired shares worth approximately $9.65 million. This key transaction was disclosed in a Form 4 filing, indicating Kim's commitment to the company amid...

Continue Reading
Delcath Systems: Recent Financial Gains and Future Growth Prospects

Updated Category News Views 154

Delcath Systems Secures Significant Funding Delcath Systems, Inc. (NASDAQ:DCTH) is making headlines with the successful exercise of Series E and E1 warrants, bringing in a notable $16.3 million. This funding marks a strategic move for the company, especially following a private placement that took place a few years ago. The timing of this financial boost couldn't be...

Continue Reading
Resolver's Innovative CSAM Detection Service Launch Explained

Updated Category News Views 348

Resolver Launches Pioneering Service for CSAM Detection Resolver, a leading provider of trust and safety intelligence, has introduced an innovative Unknown CSAM Detection Service. This service empowers platforms and services with the capability to identify and classify unknown child sexual abuse material (CSAM) with high precision. Identifying the Challenge in the Digital...

Continue Reading
HanesBrands Finalizes Sale of Champion Business to Authentic Brands

Updated Category News Views 151

HanesBrands Inc. (NYSE: HBI) wrapped up the sale of its global Champion business to Authentic Brands Group, shifting ownership of key intellectual property and assets associated with the brand. Transaction Impact: Simplification or Just Smoke? This deal isn't just another footnote in corporate history; it's a bold stroke by CEO Steve Bratspies who underscored that this...

Continue Reading
NVIDIA's Options Activity: Insights and Market Projections

Updated Category News Views 192

NVIDIA's Options Activity: Insights and Market Projections Financial giants have made a strong bullish move on NVIDIA. An analysis of options history for NVIDIA (NASDAQ: NVDA) revealed a significant number of unusual trades, indicating a growing interest among large-scale investors. As we dig deeper, we find that 45% of traders favor a bullish outlook, while 40% express...

Continue Reading